ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

Physician Indicted for Mail Fraud After allegedly Falsifying Data Of Patients On ECOG, CALGB Trials

March 30, 1984

CTEP-Approved Trials For the Month of June

June 28, 2013

“Wild West” of Molecular Testing?: Caris Engaged in Aggressive Marketing, Improper Medicare Billing, Lawsuit Alleges

August 8, 2014

Trials Approved by NCI CTEP For the Month of May

May 25, 2012

DCPC board Oks New Grant Program For Investigators

March 4, 1994

Groups Urge FDA To Take Action Against Tobacco Products

June 27, 2014